{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:23:09Z","timestamp":1791843789992,"version":"4.3.4"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n The availability of psychedelic retreats has grown to meet the demand for access to these substances. Despite centuries of use among Indigenous communities, psychedelics can pose serious risks for some users.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine safety precautions that retreat organizations that offer psychedelic substances currently use.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This qualitative study included structured interviews conducted by phone or email with representatives from 49 organizations publicly advertising psychedelic retreat offerings from July to October 2023. Organizations were eligible if they marketed their services in English, offered at least 1 psychedelic substance, and made contact information available online. Organizations were selected using convenience sampling from a broader pool of organizations identified in a prior study. Data were analyzed from March 2024 to November 2025.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcomes of interest included the types of drugs offered and presence of polysubstance use, collaboration with health care professionals, presence of health care professionals during retreats, disqualifying conditions, medication washout procedures, and integration practices. Descriptive statistics were used to characterize organizational practices and locations; content analysis was used to categorize medical exclusion criteria, medication washout protocols, involvement of health care professionals, integration offerings, and training of integration facilitators.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 48 organizations that reported what substances they offered, all offered either ayahuasca, psilocybin, or both. Nineteen organizations (38.7%) offered more than 1 psychedelic substance. All organizations collected participant medical histories; 36 organizations (73.5%) excluded individuals with certain health conditions. Most (43 organizations [87.8%]) required or recommended medication washout for varying lengths of time, ranging from 1 day to more than 6 weeks. Most (34 organizations [69.4%]) worked with a licensed health care professional or someone with emergency response training, and 32 organizations (65.3%) had someone with those qualifications in attendance at retreats at least some of the time. All organizations offered some sort of integration support.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This qualitative study of the practices implemented by psychedelic retreat organizations found substantial variability in the implementation of safety precautions. Some practices related to medication washout and polysubstance use may pose increased risks to participants. Best practice guidelines are needed and should be codeveloped with Indigenous and nonclinical communities.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.52505","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:31:05Z","timestamp":1767803465000},"page":"e2552505","source":"Crossref","is-referenced-by-count":4,"title":["Reported Safety Practices of Publicly Advertised Psychedelic Retreats"],"prefix":"10.1001","volume":"9","author":[{"given":"Amy L.","family":"McGuire","sequence":"first","affiliation":[{"name":"Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas"},{"name":"Ethical Legal Implications of Psychedelics in Society Program, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Neitzke-Spruill","sequence":"additional","affiliation":[{"name":"Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas"},{"name":"Ethical Legal Implications of Psychedelics in Society Program, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill O.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas"},{"name":"Ethical Legal Implications of Psychedelics in Society Program, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline S.","family":"Beit","sequence":"additional","affiliation":[{"name":"Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas"},{"name":"Ethical Legal Implications of Psychedelics in Society Program, Baylor College of Medicine, Houston, Texas"},{"name":"Johns Hopkins School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Singh","sequence":"additional","affiliation":[{"name":"Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas"},{"name":"Ethical Legal Implications of Psychedelics in Society Program, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Mathai","sequence":"additional","affiliation":[{"name":"Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas"},{"name":"Ethical Legal Implications of Psychedelics in Society Program, Baylor College of Medicine, Houston, Texas"},{"name":"Sattva Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnette A.","family":"Averill","sequence":"additional","affiliation":[{"name":"Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas"},{"name":"Ethical Legal Implications of Psychedelics in Society Program, Baylor College of Medicine, Houston, Texas"},{"name":"Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas"},{"name":"Michael E. DeBakey Veterans Association, Houston, Texas"},{"name":"Menninger Clinic, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"zoi251398r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109399","article-title":"The varieties of psychedelic law.","volume":"226","author":"Marks","year":"2023","journal-title":"Neuropharmacology"},{"issue":"5","key":"zoi251398r5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/02791072.2015.1094590","article-title":"Ayahuasca tourism: participants in shamanic rituals and their personality styles, motivation, benefits and risks.","volume":"47","author":"Kavensk\u00e1","year":"2015","journal-title":"J Psychoactive Drugs"},{"issue":"3","key":"zoi251398r6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/02508281.2016.1192237","article-title":"Spirituality, drugs, and tourism: tourists\u2019 and shamans\u2019 experiences of ayahuasca in Iquitos, Peru.","volume":"41","author":"Prayag","year":"2016","journal-title":"Tour Recreat Res"},{"issue":"5","key":"zoi251398r7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0321648","article-title":"A landscape analysis of psychedelic retreat organizations advertising online.","volume":"20","author":"Neitzke-Spruill","year":"2025","journal-title":"PLoS One"},{"issue":"5","key":"zoi251398r8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/00952990.2023.2220874","article-title":"Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male special operations forces veterans: prospective data from a clinical program in Mexico.","volume":"49","author":"Davis","year":"2023","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"2","key":"zoi251398r9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12152-024-09567-0","article-title":"A transformative trip: experiences of psychedelic use.","volume":"17","author":"Neitzke-Spruill","year":"2024","journal-title":"Neuroethics"},{"issue":"1","key":"zoi251398r10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1556\/2054.2024.00322","article-title":"Subjective ibogaine experiences across intersecting social-ecological dimensions.","volume":"9","author":"Ozmat","year":"2024","journal-title":"J Psychedelic Stud"},{"issue":"4","key":"zoi251398r12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3109\/15563650.2016.1138226","article-title":"How toxic is ibogaine?","volume":"54","author":"Litjens","year":"2016","journal-title":"Clin Toxicol (Phila)"},{"issue":"2","key":"zoi251398r13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s44161-025-00608-2","article-title":"Cardiovascular effects and safety of classic psychedelics.","volume":"4","author":"Nahlawi","year":"2025","journal-title":"Nat Cardiovasc Res"},{"issue":"6","key":"zoi251398r14","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1007\/s43440-023-00539-4","article-title":"Cardiovascular safety of psychedelic medicine: current status and future directions.","volume":"75","author":"Ws\u00f3l","year":"2023","journal-title":"Pharmacol Rep"},{"issue":"2","key":"zoi251398r15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/psymed.2023.0051","article-title":"A plea for nuance: should people with a family history of bipolar disorder be excluded from clinical trials of psilocybin therapy?","volume":"2","author":"Downey","year":"2024","journal-title":"Psychedelic Med (New Rochelle)"},{"key":"zoi251398r16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jad.2024.01.197","article-title":"Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom.","volume":"351","author":"Honk","year":"2024","journal-title":"J Affect Disord"},{"issue":"4","key":"zoi251398r17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/0269881121996863","article-title":"Associations between lifetime classic psychedelic use and markers of physical health.","volume":"35","author":"Simonsson","year":"2021","journal-title":"J Psychopharmacol"},{"issue":"1","key":"zoi251398r20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jep.2007.08.034","article-title":"The ibogaine medical subculture.","volume":"115","author":"Alper","year":"2008","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"zoi251398r21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/02791072.2013.873157","article-title":"Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence\u2013qualitative results.","volume":"46","author":"Loizaga-Velder","year":"2014","journal-title":"J Psychoactive Drugs"},{"key":"zoi251398r22","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320986634","article-title":"Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine.","author":"O\u2019Shaughnessy","year":"2021","journal-title":"Ther Adv Psychopharmacol"},{"key":"zoi251398r23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.659644","article-title":"Protocol for outcome evaluation of ayahuasca-assisted addiction treatment: the case of Takiwasi Center.","volume":"12","author":"Rush","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"zoi251398r24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/15733998113099990003","article-title":"Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada.","volume":"6","author":"Thomas","year":"2013","journal-title":"Curr Drug Abuse Rev"},{"issue":"4","key":"zoi251398r25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.drugpo.2006.11.001","article-title":"The globalization of ayahuasca: harm reduction or benefit maximization?","volume":"19","author":"Tupper","year":"2008","journal-title":"Int J Drug Policy"},{"issue":"2","key":"zoi251398r26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/02698811231224217","article-title":"Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study.","volume":"38","author":"Barbut Siva","year":"2024","journal-title":"J Psychopharmacol"},{"issue":"6","key":"zoi251398r27","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","article-title":"Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans.","volume":"14","author":"Bonson","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"zoi251398r28","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1177\/02698811231179910","article-title":"Attenuation of psilocybin mushroom effects during and after SSRI\/SNRI antidepressant use.","volume":"37","author":"Gukasyan","year":"2023","journal-title":"J Psychopharmacol"},{"issue":"6","key":"zoi251398r29","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s00213-021-05876-x","article-title":"Serotonin toxicity of serotonergic psychedelics.","volume":"239","author":"Malcolm","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"zoi251398r30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1080\/03602532.2019.1697283","article-title":"Adverse pharmacokinetic interactions between illicit substances and clinical drugs.","volume":"52","author":"Abbott","year":"2020","journal-title":"Drug Metab Rev"},{"issue":"4","key":"zoi251398r31","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cpt.2487","article-title":"Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects.","volume":"111","author":"Becker","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"zoi251398r32","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"zoi251398r33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/02698811231211219","article-title":"Drug-drug interactions involving classic psychedelics: a systematic review.","volume":"38","author":"Halman","year":"2024","journal-title":"J Psychopharmacol"},{"issue":"2","key":"zoi251398r34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40263-022-00960-y","article-title":"Estimating risk of antidepressant withdrawal from a review of published data.","volume":"37","author":"Horowitz","year":"2023","journal-title":"CNS Drugs"},{"key":"zoi251398r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115303","article-title":"The need for antidepressant withdrawal support services: Recommendations from 708 patients.","volume":"326","author":"Read","year":"2023","journal-title":"Psychiatry Res"},{"issue":"1","key":"zoi251398r36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12888-024-06303-z","article-title":"Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report.","volume":"25","author":"Perna","year":"2025","journal-title":"BMC Psychiatry"},{"issue":"2","key":"zoi251398r37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0378-8741(84)90036-9","article-title":"The concept of plants as teachers among four mestizo shamans of Iquitos, northeastern Peru.","volume":"11","author":"Luna","year":"1984","journal-title":"J Ethnopharmacol"},{"issue":"5","key":"zoi251398r38","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1080\/03080188.2022.2075201","article-title":"\u2018Everybody\u2019s creating it along the way\u2019: ethical tensions among globalized ayahuasca shamanisms and therapeutic integration practices.","volume":"48","author":"Marcus","year":"2023","journal-title":"Interdiscip Sci Rev"},{"key":"zoi251398r11","first-page":"269","volume-title":"The ASAM Principles of Addiction Medicine","author":"Yaden","year":"2024","edition":"7th ed"},{"key":"zoi251398r18","volume-title":"Ayahuasca Global Consumption & Reported Deaths: A Rough Estimate of the Number of People Drinking Ayahuasca Worlswide and Anlaysis of Fatalities Reported in the Media","author":"\u00c1lvarez","year":"2023"},{"key":"zoi251398r19","volume-title":"Content Analysis: An Introduction to Its Methodology","author":"Krippendorff","year":"2018"},{"key":"zoi251398r39","volume-title":"The Fellowship of the River: A Medical Doctor\u2019s Exploration Into Traditional Amazonian Plant Medicine","author":"Tafur","year":"2017"},{"key":"zoi251398r1","unstructured":"Schumaker? E. RFK Jr. is bringing psychedelics to the Republican Party. Politico. June 29, 2025. Accessed July 1, 2025. https:\/\/www.politico.com\/news\/2025\/06\/29\/rfk-psychedelics-ecstasy-ibogaine-veterans-00429997"},{"key":"zoi251398r2","doi-asserted-by":"crossref","unstructured":"Patrick? ME, Miech? RA, Johnston? LD, O\u2019Malley? PM. Monitoring the Future Panel Study annual report: national data on substance use among adults ages 19 to 65, 1976-2023. Accessed July 1, 2025. https:\/\/monitoringthefuture.org\/results\/annual-reports\/","DOI":"10.7826\/ISR-UM.06.585140.002.07.0003.2024"},{"key":"zoi251398r4","unstructured":"Kenny? A. A gray market emerges in Colorado after voters approved psychedelic substances. NPR. July 4, 2023. Accessed February 6, 2024. https:\/\/www.npr.org\/2023\/07\/04\/1185922732\/a-gray-market-emerges-in-colorado-after-voters-approved-psychedelic-substances"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2843513\/mcguire_2026_oi_251398_1766777441.57661.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:31:07Z","timestamp":1767803467000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2843513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.52505","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]}}}